Step 1
Our platform, DPX, has advanced a new class of immunotherapies that can be leveraged in multiple diseases and markets. In a proprietary process, we encapsulate active ingredients within our patented delivery technology.
DPX, A Fully Synthetic Delivery Platform
Generating Targeted, Robust and Sustained Immune Responses
At IMV, we believe we have found the key to bolster and direct the power of human immunity against diseases. Our bodies are hardwired with an elegant way to combat serious diseases and our novel platform makes use of it by delivering instructions to the immune system in a way that enables robust, targeted, and long-lasting response against specific targets.
Our proprietary technology is a unique “No-release” lipid-based delivery platform with no aqueous component in the final formulation. When administered, our formulation does not release components at the injection site, which allows it to continuously interact with and stimulate the immune system over an extended period of time. Thus, producing a more rapid, robust, and sustained immune response against specific disease targets.
Key Benefits of Our Powerful, Versatile Platform
We believe the method of delivering instructions to the human immune system is the differentiator that can create pivotal, sustained responses. Our DPX™ Platform has the potential to effectively deliver information that generates a target-specific immune response.
Our platform has multiple unique advantages over other immunotherapies.
- Can safely increase the immune system’s exposure to practically any antigen.
- Demonstrates a good safety profile and sustained immunological activity across all clinical trials in diverse cancer and infectious disease indications.
- Can readily be combined with other immunotherapeutic approaches, including checkpoint inhibitors.
- May need fewer administrations compared to other available immunotherapies, and some indications have the potential for single-dose effectiveness.
- Have shown efficacy in vulnerable populations, like older adults and immune-compromised.
DPX-based products
- are stored in dry form and reconstituted in oil for injection
- have an extended shelf life
- are simple to handle in a clinic setting (subcutaneous injection, no hospitalization)
- are fully synthetic: relatively easy, fast and cost-effective to manufacture
Deployable for Diverse Diseases and Markets
Our ability to activate the human immune system in a powerful and precise way is promising for not only cancer but infectious diseases, allergic responses and more. Presently, we are working with multiple partners to develop a clinical asset pipeline outside of oncology.